MILANO VINCENT 4

4 · Aclaris Therapeutics, Inc. · Filed Jun 8, 2026

AI-generated summary of this filing

Updated Jun 8, 2026

Aclaris (ACRS) Director Vincent Milano Receives Awards, Exercises Options

What Happened

Vincent Milano, a director of Aclaris Therapeutics (ACRS), received equity awards and completed a derivative exercise. On June 4, 2026 Milano was granted two restricted stock unit (RSU) awards totaling 53,337 RSUs (42,350 and 10,987 RSUs) reported at $0.00 (derivative awards). On June 5, 2026 the filing reports an exercise/conversion of 11,580 derivative securities; those 11,580 shares were recorded as immediately disposed (reported at $0.00 in the filing).

Key Details

Transaction dates: RSU grants recorded 2026-06-04; exercise/conversion and disposition recorded 2026-06-05. Filing date: 2026-06-08.
Prices/values reported: Grants shown at $0.00 (derivative awards). Exercise/disposition reported at $0.00 in the filing (no cash amount reported).
Shares owned after the transactions: Not specified in the filing.
Notable footnotes from the filing:
- F1: Each RSU represents a contingent right to one share of common stock.
- F3: The 6/4 grant was made under the issuer’s non-employee director compensation policy.
- F4: The 42,350-RSU award vests in one installment on June 4, 2027, subject to continued service.
- F5: The shares underlying one RSU award (10,987) vested on June 5, 2026.
- F2 references an option vesting schedule (12 monthly installments beginning July 4, 2026) tied to another award in the filing.
Timeliness: Filing appears timely (transactions in early June, Form 4 filed June 8, 2026).

Context

The filing shows both award grants (RSUs) and a derivative exercise/conversion with an immediate disposition of the resulting shares. Immediate disposition of exercised shares is commonly reported when shares are sold or transferred at or near conversion (the filing reports the disposition at $0.00). The 6/4 grants are director compensation awards and include a mix of immediate vesting (per F5) and future vesting (per F4). This filing is informational and does not by itself indicate the director’s investment sentiment.

Form 4

Period: 2026-06-04

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-06-05+11,580→ 28,896 total
Award
Stock Option (Right to Buy)
[F2][F3]
2026-06-04+42,350→ 42,350 total
Exercise: $4.71Exp: 2036-06-03→ Common Stock (42,350 underlying)
Award
Restricted Stock Units
[F1][F4][F3]
2026-06-04+10,987→ 10,987 total
→ Common Stock (10,987 underlying)
Exercise/Conversion
Restricted Stock Units
[F1][F5]
2026-06-05−11,580→ 0 total
→ Common Stock (11,580 underlying)

Footnotes (5)

[F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
[F2]The shares subject to this stock option will vest in twelve equal monthly installments commencing on July 4, 2026, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2025 Equity Incentive Plan, or the Plan) through each such vesting date.
[F3]This grant was made pursuant to the issuer's tenth amended and restated non-employee director compensation policy.
[F4]The shares underlying these restricted stock units will vest in one installment on June 4, 2027, subject to the Reporting Person's Continuous Service (as defined in the Plan) as of such date.
[F5]The shares underlying these restricted stock units vested on June 5, 2026.

Signature

/s/ Matthew Rothman, Attorney-in-Fact|2026-06-08

1 file